MYLAN-MEMANTINE TABLET

Երկիր: Կանադա

Լեզու: անգլերեն

Աղբյուրը: Health Canada

Ակտիվ բաղադրիչ:

MEMANTINE HYDROCHLORIDE

Հասանելի է:

MYLAN PHARMACEUTICALS ULC

ATC կոդը:

N06DX01

INN (Միջազգային անվանումը):

MEMANTINE

Դոզան:

10MG

Դեղագործական ձեւ:

TABLET

Կազմը:

MEMANTINE HYDROCHLORIDE 10MG

Կառավարման երթուղին:

ORAL

Միավորները փաթեթում:

100

Ռեկվիզորի տեսակը:

Prescription

Թերապեւտիկ տարածք:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Ապրանքի ամփոփագիր:

Active ingredient group (AIG) number: 0150423001; AHFS:

Լիազորման կարգավիճակը:

CANCELLED POST MARKET

Հաստատման ամսաթիվը:

2017-05-08

Ապրանքի հատկությունները

- 1 -
PRODUCT MONOGRAPH
Pr
MYLAN-MEMANTINE
Memantine Hydrochloride Tablets
10 mg
Professed
N-methyl-D-aspartate (NMDA) receptor antagonist
Mylan Pharmaceuticals ULC
Date of Revision:
85 Advance Road,
December 21, 2015
Etobicoke, Ontario,
M8Z 2S6
CONTROL NO. 190639
- 2 -
NAME OF
DRUG
PR
MYLAN-MEMANTINE
Memantine Hydrochloride Tablets
10 mg
THERAPEUTIC CLASSIFICATION
N-methyl-D-aspartate (NMDA) receptor
antagonist
A
CTION AND
C
LINICAL
P
HARMACOLOGY
Persistent activation of the central nervous system
N-methyl-D-aspartate (NMDA) receptors
by the excitatory amino acid glutamate has been hypothesized to
contribute to
the symptomatology of Alzheimer’s disease. Memantine is postulated
to exert its therapeutic
effect through its action as a low to moderate affinity uncompetitive
(open channel) NMDA
receptor antagonist, which binds preferentially to the NMDA
receptor-operated cation
channels. It blocks the effects of pathologically elevated sustained
levels of glutamate that
may lead to neuronal dysfunction. There is no clinical evidence that
memantine prevents or
slows neurodegeneration or alters the course of the underlying
dementing process in patients
with Alzheimer’s disease. Memantine exhibits low to negligible
affinity for other receptors
(GABA, benzodiazepine, dopamine, adrenergic, noradrenergic, histamine
and glycine) or
voltage-dependent Ca
2+
, Na
+
or K
+
channels. In addition, it does not directly affect the
acetylcholine receptor or cholinergic transmission, which have been
implicated in the
cholinomimetic side effects (e.g., increased gastric acid secretion,
nausea and vomiting) seen
with acetylcholinesterase inhibitors. Memantine showed antagonist
effects at the 5HT
3
receptor with a potency similar to that for the NMDA receptor.
- 3 -
_In vitro_ studies have shown that memantine does not affect the
reversible inhibition of
acetylcholinesterase by donepezil or galantamine.
P
HARMACOKINETICS
ABSORPTION
Orally administered memantine is completely absorbed. Oral
bioavailability is almost
100%. Time to max